{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:12:55Z","timestamp":1776352375092,"version":"3.51.2"},"reference-count":105,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,1]],"date-time":"2027-04-01T00:00:00Z","timestamp":1806537600000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI143965"],"award-info":[{"award-number":["AI143965"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.iac.2026.01.012","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:50:35Z","timestamp":1773147035000},"page":"357-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Therapies for Anaphylaxis"],"prefix":"10.1016","volume":"46","author":[{"given":"Melanie C.","family":"Dispenza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iac.2026.01.012_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/ACI.0b013e3283036a90","article-title":"Understanding the mechanisms of anaphylaxis","volume":"8","author":"Peavy","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.01.012_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0065-2776(08)00403-3","article-title":"New insights on mast cell activation via the high affinity receptor for IgE","volume":"98","author":"Rivera","year":"2008","journal-title":"Adv Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.012_bib4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2021.02.012","article-title":"Non-IgE-mediated anaphylaxis","volume":"147","author":"Cianferoni","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2026.01.012_bib5","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jaci.2016.02.015","article-title":"Human IgE-independent systemic anaphylaxis","volume":"137","author":"Finkelman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.18176\/jiaci.0046","article-title":"Mechanisms of anaphylaxis beyond IgE","volume":"26","author":"Munoz-Cano","year":"2016","journal-title":"J Invest Allergol Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib7","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jid.2020.09.017","article-title":"MRGPRX2 is the codeine receptor of human skin mast cells: desensitization through beta-arrestin and lack of correlation with the FcepsilonRI pathway","volume":"141","author":"Babina","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29965-8","article-title":"MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia","volume":"8","author":"Navines-Ferrer","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.iac.2026.01.012_bib9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"Subramanian","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"7542","key":"10.1016\/j.iac.2026.01.012_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.iac.2026.01.012_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/cea.70068","article-title":"Variants of the MRGPRX2 gene found in patients with hypersensitivity to quinolones and Vancomycin show amplified and drug-specific activation responses in vitro","volume":"55","author":"Quan","year":"2025","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.iac.2026.01.012_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.intimp.2010.12.018","article-title":"Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton\u2019s tyrosine kinase, Btk, inhibitor","volume":"11","author":"MacGlashan","year":"2011","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"10.1016\/j.iac.2026.01.012_bib13","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton\u2019s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.012_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2017.03.013","article-title":"Ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity","volume":"140","author":"Regan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib16","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.jaci.2017.12.987","article-title":"Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy","volume":"141","author":"Dispenza","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jaip.2022.10.017","article-title":"Pretreatment with ibrutinib facilitates rapid drug desensitization in a difficult case of brentuximab vedotin-induced anaphylaxis","volume":"11","author":"Rodsaward","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaci.2024.03.010","article-title":"Prevention of allergic reactions during oxaliplatin desensitization through inhibition of Bruton tyrosine kinase","volume":"154","author":"Erickson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2025.07.003","article-title":"The Bruton\u2019s tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice","volume":"156","author":"Arce","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.012_bib20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2025.05.030","article-title":"Current and future landscape of Bruton tyrosine kinase inhibitors in allergy","volume":"156","author":"Lin","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.01.012_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.iac.2026.01.012_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106577","article-title":"Recent research of BTK inhibitors: methods of structural design, pharmacological activities, manmade derivatives and structure\u2013activity relationship","volume":"138","author":"Wang","year":"2023","journal-title":"Bioorg Chem"},{"issue":"21","key":"10.1016\/j.iac.2026.01.012_bib23","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1073\/pnas.94.21.11526","article-title":"Phosphorylation of two regulatory tyrosine residues in the activation of Bruton\u2019s tyrosine kinase via alternative receptors","volume":"94","author":"Wahl","year":"1997","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton\u2019s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.iac.2026.01.012_bib25","series-title":"Rilzabrutinib reduces IgG Anti- thyroid peroxidase (anti-TPO), soluble Mas-Related G Protein- coupled receptor X2 (sMRGPRX2), and eosinophils at 12 weeks in patients with chronic spontaneous urticaria","author":"Maurer","year":"2024"},{"issue":"11","key":"10.1016\/j.iac.2026.01.012_bib26","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.iac.2026.01.012_bib27","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the bruton\u2019s tyrosine kinase inhibitor Fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.iac.2026.01.012_bib28","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.iac.2026.01.012_bib29","series-title":"Paper presented at: Americas Committee for treatment and research in multiple sclerosis (ACTRIMS) forum","article-title":"Effect of remibrutinib treatment on the immune response to vaccinations in healthy participants","author":"Tillmann","year":"2025"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy and Clinical Immunology"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","article-title":"Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis","volume":"94","author":"Montalban","year":"2023","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"10","key":"10.1016\/j.iac.2026.01.012_bib32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.iac.2026.01.012_bib33","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/cts.13524","article-title":"Rilzabrutinib, a reversible covalent Bruton\u2019s tyrosine kinase inhibitor: absorption, metabolism, excretion, and absolute bioavailability in healthy participants","volume":"16","author":"Ucpinar","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.iac.2026.01.012_bib34","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton Tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.iac.2026.01.012_bib35","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jaci.2008.04.019","article-title":"Inducing an anergic state in mast cells and basophils without secretion","volume":"121","author":"MacGlashan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4193\/Rhino09.147","article-title":"Syk-kinase inhibition prevents mast cell activation in nasal polyps","volume":"49","author":"Patou","year":"2011","journal-title":"Rhinology"},{"issue":"3","key":"10.1016\/j.iac.2026.01.012_bib37","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.immuni.2014.05.017","article-title":"Immunoglobulin E signal inhibition during allergen ingestion leads to reversal of established food allergy and induction of regulatory T cells","volume":"41","author":"Burton","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.iac.2026.01.012_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.taap.2017.07.015","article-title":"Suppression of IgE-mediated mast cell activation and mouse anaphylaxis via inhibition of syk activation by 8-formyl-7-hydroxy-4-methylcoumarin, 4mu8C","volume":"332","author":"Nam","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/all.12786","article-title":"NecroX-5 suppresses IgE\/Ag-stimulated anaphylaxis and mast cell activation by regulating the SHP-1-Syk signaling module","volume":"71","author":"Li","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2026.01.012_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.02.048","article-title":"JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking","volume":"801","author":"Kato","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.iac.2026.01.012_bib42","doi-asserted-by":"crossref","unstructured":"Karra L, Levi-Schaffer F. Down-regulation of mast cell responses through ITIM containing inhibitory receptors. Vol 716. Boston, MA: Springer; 2011.","DOI":"10.1007\/978-1-4419-9533-9_9"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12016-018-8678-z","article-title":"The use of biomarkers to predict aero-allergen and food immunotherapy responses","volume":"55","author":"Sindher","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.iac.2026.01.012_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972103","article-title":"Biomarkers and mechanisms of tolerance induction in food allergic patients drive new therapeutic approaches","volume":"13","author":"Baloh","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.iac.2026.01.012_bib45","article-title":"High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy","volume":"2","author":"Chen","year":"2021","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.iac.2026.01.012_bib46","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1172\/JCI25575","article-title":"IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking","volume":"116","author":"Strait","year":"2006","journal-title":"J Clin Investig"},{"key":"10.1016\/j.iac.2026.01.012_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603050","article-title":"IgE and IgG antibodies as regulators of mast cell and basophil functions in food allergy","volume":"11","author":"Kanagaratham","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1172\/JCI117701","article-title":"Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors","volume":"95","author":"Daeron","year":"1995","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/cea.12155","article-title":"Regulation of IgE-mediated signalling in human basophils by CD32b and its role in Syk down-regulation: basic mechanisms in allergic disease","volume":"44","author":"Macglashan","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.iac.2026.01.012_bib50","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaci.2014.05.042","article-title":"Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity","volume":"134","author":"Burton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.012_bib51","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jaci.2015.10.043","article-title":"Parameters determining the efficacy of CD32 to inhibit activation of FcepsilonRI in human basophils","volume":"137","author":"MacGlashan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.01.012_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2024.1389669","article-title":"Allergen-specific IgA and IgG antibodies as inhibitors of mast cell function in food allergy","volume":"5","author":"Furiness","year":"2024","journal-title":"Front Allergy"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib53","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jaci.2024.07.014","article-title":"Preclinical efficacy of peanut-specific IgG4 antibody therapeutic IGNX001","volume":"154","author":"Croote","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib54","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41467-018-03636-8","article-title":"Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement","volume":"9","author":"Orengo","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaci.2021.05.038","article-title":"Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response","volume":"149","author":"Atanasio","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2021.05.039","article-title":"Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2026.01.012_bib57","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jaci.2022.06.025","article-title":"REGN1908\/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit","volume":"150","author":"de Blay","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2026.01.012_bib58","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1398-9995.2004.00332.x","article-title":"A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils","volume":"59","author":"Tam","year":"2004","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib59","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm0502-518","article-title":"A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation","volume":"8","author":"Zhu","year":"2002","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib60","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jaci.2007.04.019","article-title":"Modifications to an Fcgamma-Fcvarepsilon fusion protein alter its effectiveness in the inhibition of FcvarepsilonRI-mediated functions","volume":"120","author":"Allen","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.imlet.2012.01.008","article-title":"Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcgammaRIIb","volume":"143","author":"Cemerski","year":"2012","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2012.10.018","article-title":"Blockade of peanut allergy with a novel Ara h 2-Fcgamma fusion protein in mice","volume":"131","author":"Liu","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/JLB.2MR0120-352RR","article-title":"Eosinophil and mast cell Siglecs: from biology to drug target","volume":"108","author":"O'Sullivan","year":"2020","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib64","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.immuni.2020.01.012","article-title":"Human mast cell proteome reveals unique lineage, putative functions, and structural basis for cell ablation","volume":"52","author":"Plum","year":"2020","journal-title":"Immunity"},{"issue":"6 Pt 1","key":"10.1016\/j.iac.2026.01.012_bib65","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1067\/mai.2000.107127","article-title":"Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils","volume":"105","author":"Kikly","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib66","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1074\/jbc.275.2.861","article-title":"Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily","volume":"275","author":"Floyd","year":"2000","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.iac.2026.01.012_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071138","article-title":"Functional and phenotypic characterization of Siglec-6 on human mast cells","volume":"11","author":"Robida","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib68","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaci.2007.10.004","article-title":"Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement","volume":"121","author":"Yokoi","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.01.012_bib69","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.3389\/fimmu.2018.02138","article-title":"Functional inhibitory Siglec-6 is upregulated in human colorectal cancer-associated mast cells","volume":"9","author":"Yu","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaci.2014.03.031","article-title":"Siglec-7 is an inhibitory receptor on human mast cells and basophils","volume":"134","author":"Mizrahi","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.012_bib71","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1172\/JCI125456","article-title":"CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen","volume":"129","author":"Duan","year":"2019","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib73","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2008.00742.x","article-title":"The tyrosine kinase network regulating mast cell activation","volume":"228","author":"Gilfillan","year":"2009","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib74","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1385\/IR:34:2:97","article-title":"Development, migration, and survival of mast cells","volume":"34","author":"Okayama","year":"2006","journal-title":"Immunol Res"},{"key":"10.1016\/j.iac.2026.01.012_bib75","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fimmu.2019.00821","article-title":"Mast cells and their progenitors in allergic asthma","volume":"10","author":"Mendez-Enriquez","year":"2019","journal-title":"Front Immunol"},{"issue":"1\u20133","key":"10.1016\/j.iac.2026.01.012_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12026-008-8046-9","article-title":"Amplification mechanisms for the enhancement of antigen-mediated mast cell activation","volume":"43","author":"Gilfillan","year":"2009","journal-title":"Immunol Res"},{"issue":"8","key":"10.1016\/j.iac.2026.01.012_bib77","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2004-02-0631","article-title":"Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells","volume":"104","author":"Hundley","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib78","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib79","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.iac.2026.01.012_bib80","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib81","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.18632\/oncotarget.3074","article-title":"Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia","volume":"6","author":"Cerny-Reiterer","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.iac.2026.01.012_bib82","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.iac.2026.01.012_bib83","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/all.16598","article-title":"Anti-KIT barzolvolimab for chronic spontaneous urticaria","volume":"80","author":"Maurer","year":"2025","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib84","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.012_bib86","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","article-title":"KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation","volume":"13","author":"Miettinen","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib87","first-page":"219","article-title":"Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin"},{"issue":"12","key":"10.1016\/j.iac.2026.01.012_bib88","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.it.2012.09.008","article-title":"New models for analyzing mast cell functions in vivo","volume":"33","author":"Reber","year":"2012","journal-title":"Trends Immunol"},{"issue":"8","key":"10.1016\/j.iac.2026.01.012_bib89","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s10815-021-02181-6","article-title":"Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review","volume":"38","author":"Rambhatla","year":"2021","journal-title":"J Assist Reprod Genet"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102131","article-title":"New insights of target therapy: effects of tyrosine kinase inhibitors on Male gonadal function: a systematic review","volume":"22","author":"Marino","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"10.1016\/j.iac.2026.01.012_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243045","article-title":"Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a systematic review","volume":"15","author":"Szakacs","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.iac.2026.01.012_bib92","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040559","article-title":"Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity","volume":"40","author":"Galli","year":"2010","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib93","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70031","article-title":"Structural and functional insights into IgE receptor interactions and disruptive inhibition","volume":"331","author":"Eggel","year":"2025","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.iac.2026.01.012_bib94","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2014.02.005","article-title":"Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib95","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2019.11.002","article-title":"Disruptive anti-IgE inhibitors prevent mast cell-dependent early airway response in viable atopic lung tissue","volume":"145","author":"Delgado","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2026.01.012_bib96","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/all.15270","article-title":"FcepsilonRI- and MRGPRX2-evoked acute degranulation responses are fully additive in human skin mast cells","volume":"77","author":"Babina","year":"2022","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2026.01.012_bib97","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaci.2024.11.021","article-title":"MRGPRX2 facilitates IgE-mediated systemic anaphylaxis in a newly established knock-in mouse model","volume":"155","author":"Bawazir","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.012_bib98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2025.03.007","article-title":"MRGPRX2 gain-of-function mutation drives enhanced mast cell reactivity in chronic spontaneous urticaria","volume":"156","author":"Ye","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.01.012_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1033794","article-title":"Inhibition of MRGPRX2 but not FcepsilonRI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist","volume":"13","author":"Bawazir","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.012_bib100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/JLB.2AB1018-405R","article-title":"Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells","volume":"106","author":"Ogasawara","year":"2019","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.012_bib101","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2022.12.805","article-title":"Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction","volume":"151","author":"Kumar","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.012_bib102","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","article-title":"Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists","volume":"154","author":"Wollam","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib103","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cell.2020.01.003","article-title":"An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe asthma","volume":"180","author":"Maun","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.iac.2026.01.012_bib104","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/cts.13163","article-title":"Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: a randomized trial","volume":"15","author":"Rymut","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"11","key":"10.1016\/j.iac.2026.01.012_bib105","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1111\/all.16309","article-title":"Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma","volume":"79","author":"Rhee","year":"2024","journal-title":"Allergy"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:31:12Z","timestamp":1776349872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856126000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0889856126000123"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2026.01.012","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapies for Anaphylaxis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2026.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}